Language:

Daily summary of financings for therapeutic biotechnology company executives and investors

Collabrity Biopharma Private-PIPE Analysis

Thursday, January 15, 2026

Agenus’s $141 Million Venture Financing

MetaVia’s $8 Million Public Offering

Wednesday, January 14, 2026

Caldera’s $112 Million Series A-1

Plus’s $15 Million Public Offering

Beyond’s $5 Million Private Placement

Tuesday, January 13, 2026

Nuclera’s $87 Million Series C

Proxima’s $80 Million Seed Round

Pelthos’s $50 Million Debt Financing

Foghorn’s $50 Million Registered Direct Offering

BriaCell’s $30 Million Public Offering

Converge’s $25 Million Series A

RISA’s $11 Million Series A

Vivere’s $10 Million Fund Raise

Enspire’s $10 Million Series B1

Monday, January 12, 2026

Mirador’s $250 Million Series B

Precede’s $83 Million Series B

Inquis’s $75 Million Series C

Oricell’s $70 Million Series C

Vibrant’s $61 Million Series B

Trailhead’s $40 Million Fund Raise

Juvena’s $33 Million Series B

Dogwood’s $27 Million Registered Direct Offering

OutSee’s $3 Million Seed Round

Saturday, January 10, 2026

Aktis’s $318 Million IPO

Kinaset’s $103 Million Series B

Friday, January 9, 2026

Orca’s $250 Million Series F
Haemonetics’s $215 Million Acquisition of Vivasure

AirNexis’s $200 Million Series A

Medipost’s $140 Million Fund Raise

Curis’s $81 Million Private Placement

Aptevo’s $60 Million Equity Investment

Clene’s $28 Million Registered Direct Offering

iBio $26 Million Private Placement

Aurora’s $16 Million Seed Round

Find’s $7 Million Series A

Thursday, January 8, 2026

Lily’s $1.2Billion Acquisition of Ventyx

Parabilis $305Million Series F

BiomX’s $3 Million Private Placement

Monday, December 29, 2025

Sanofi’s $2 Billion Acquisition of Dynavax

Dermata’s $12 Million Private Placement

Indaptus’s $6 Million Equity Investment

Tuesday, December 23, 2025

Rznomics’s $31 Million IPO

Vyriad’s $25 Million Series B

Theralase®’s $1 Million Private Placement

Monday, December 22, 2025

Celularity’s $10 Million Debt Financing

RheumaGen’s Series A-1

Friday, December 19, 2025

Kodiak’s $184 Million Public Offering

Aktis’s $100 Million IPO

Mirum’s $69 Million Private Placement

IN8bio’s $40 Million Private Placement

Cue’s $10 Million Public Offering

BioMarin’s $4.8 Billion Acquisition of Amicus

GeoVax’s $3 Million Public Offering

Thursday, December 18, 2025

Kodiak’s $184 Million Public Offering

Syremis’s $165 Million Series A

Atavistik’S $120 Million Series B

Syneron’s $100 Million Series A and A+

Orum’s $100 Million Equity Investment

FoRx’s $50 Million Series A

CAMP4’D $30 Million Public Offering

Rezubio’s $20 Million Series A

Amphix’s $12 Million Seed Round

Biodexa’s $10 Million Public Offering

Lixte’s $4 Million Registered Direct Offering

Wednesday, December 17, 2025

Ambros’s $125 Million Series A

Kyverna’s $100 Million Public Offering

Alvotech’s $100 Million Debt Financing

Addition’s $100M Series A

Aeovian’s $55 Million Series B

Invea’s $35 Million IPO

T-CURX’s $20 Million Series A

DNA’s $3 Million Seed Round

FibroBiologics’s $2 Million Registered Direct Offering

MAIA’s $1 Million Private Placement

Collabrity Report 2025 – 2026,
All Rights Reserved

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.

Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck  | Finalis Form Customer Relationship Summary (“Form CRS”)

collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.

Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.